Search

Your search keyword '"Sevilla MÁ"' showing total 46 results
Start Over Author "Sevilla MÁ"
46 results on '"Sevilla MÁ"'

6. Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes

Author

Hindy, George, Dornbos, Peter, Chaffin, Mark D., Liu, Dajiang J., Wang, Minxian, Selvaraj, Margaret Sunitha, Zhang, David, Park, Joseph, Aguilar-Salinas, Carlos A., Antonacci-Fulton, Lucinda, Ardissino, Diego, Arnett, Donna K., Aslibekyan, Stella, Atzmon, Gil, Ballantyne, Christie M., Barajas-Olmos, Francisco, Barzilai, Nir, Becker, Lewis C., Bielak, Lawrence F., Bis, Joshua C., Blangero, John, Boerwinkle, Eric, Bonnycastle, Lori L., Bottinger, Erwin, Bowden, Donald W., Bown, Matthew J., Brody, Jennifer A., Broome, Jai G., Burtt, Noël P., Cade, Brian E., Centeno-Cruz, Federico, Chan, Edmund, Chang, Yi-Cheng, Chen, Yii-Der I., Cheng, Ching-Yu, Choi, Won Jung, Chowdhury, Rajiv, Contreras-Cubas, Cecilia, Córdova, Emilio J., Correa, Adolfo, Cupples, L. Adrienne, Curran, Joanne E., Danesh, John, de Vries, Paul S., DeFronzo, Ralph A., Doddapaneni, Harsha, Duggirala, Ravindranath, Dutcher, Susan K., Ellinor, Patrick T., Emery, Leslie S., Florez, Jose C., Fornage, Myriam, Freedman, Barry I., Fuster, Valentin, Garay-Sevilla, Ma. Eugenia, García-Ortiz, Humberto, Germer, Soren, Gibbs, Richard A., Gieger, Christian, Glaser, Benjamin, Gonzalez, Clicerio, Gonzalez-Villalpando, Maria Elena, Graff, Mariaelisa, Graham, Sarah E., Grarup, Niels, Groop, Leif C., Guo, Xiuqing, Gupta, Namrata, Han, Sohee, Hanis, Craig L., Hansen, Torben, He, Jiang, Heard-Costa, Nancy L., Hung, Yi-Jen, Hwang, Mi Yeong, Irvin, Marguerite R., Islas-Andrade, Sergio, Jarvik, Gail P., Kang, Hyun Min, Kardia, Sharon L.R., Kelly, Tanika, Kenny, Eimear E., Khan, Alyna T., Kim, Bong-Jo, Kim, Ryan W., Kim, Young Jin, Koistinen, Heikki A., Kooperberg, Charles, Kuusisto, Johanna, Kwak, Soo Heon, Laakso, Markku, Lange, Leslie A., Lee, Jiwon, Lee, Juyoung, Lee, Seonwook, Lehman, Donna M., Lemaitre, Rozenn N., Linneberg, Allan, Liu, Jianjun, Loos, Ruth J.F., Lubitz, Steven A., Lyssenko, Valeriya, Ma, Ronald C.W., Martin, Lisa Warsinger, Martínez-Hernández, Angélica, Mathias, Rasika A., McGarvey, Stephen T., McPherson, Ruth, Meigs, James B., Meitinger, Thomas, Melander, Olle, Mendoza-Caamal, Elvia, Metcalf, Ginger A., Mi, Xuenan, Mohlke, Karen L., Montasser, May E., Moon, Jee-Young, Moreno-Macías, Hortensia, Morrison, Alanna C., Muzny, Donna M., Nelson, Sarah C., Nilsson, Peter M., O’Connell, Jeffrey R., Orho-Melander, Marju, Orozco, Lorena, Palmer, Colin N.A., Palmer, Nicholette D., Park, Cheol Joo, Park, Kyong Soo, Pedersen, Oluf, Peralta, Juan M., Peyser, Patricia A., Post, Wendy S., Preuss, Michael, Psaty, Bruce M., Qi, Qibin, Rao, D.C., Redline, Susan, Reiner, Alexander P., Revilla-Monsalve, Cristina, Rich, Stephen S., Samani, Nilesh, Schunkert, Heribert, Schurmann, Claudia, Seo, Daekwan, Seo, Jeong-Sun, Sim, Xueling, Sladek, Rob, Small, Kerrin S., So, Wing Yee, Stilp, Adrienne M., Tai, E. Shyong, Tam, Claudia H.T., Taylor, Kent D., Teo, Yik Ying, Thameem, Farook, Tomlinson, Brian, Tsai, Michael Y., Tuomi, Tiinamaija, Tuomilehto, Jaakko, Tusié-Luna, Teresa, Udler, Miriam S., van Dam, Rob M., Vasan, Ramachandran S., Viaud Martinez, Karine A., Wang, Fei Fei, Wang, Xuzhi, Watkins, Hugh, Weeks, Daniel E., Wilson, James G., Witte, Daniel R., Wong, Tien-Yin, Yanek, Lisa R., Kathiresan, Sekar, Rader, Daniel J., Rotter, Jerome I., Boehnke, Michael, McCarthy, Mark I., Willer, Cristen J., Natarajan, Pradeep, Flannick, Jason A., Khera, Amit V., and Peloso, Gina M.

Published
2022
Full Text
View/download PDF

7. Increased visceral fat accumulation modifies the effect of insulin resistance on arterial stiffness and hypertension risk

Author

Arellano-Campos, Olimpia, Gómez-Velasco, Donaji V., Bello-Chavolla, Omar Yaxmehen, Viveros-Ruiz, Tania, Martagón-Rosado, Alexandro J., Cruz-Bautista, Ivette, Melgarejo-Hernandez, Marco A., Almeda-Valdés, Paloma, Muñoz-Hernandez, Liliana, Elias-Lopez, Daniel, Del Razo-Olvera, Fabiola Mabel, Encinas, Bethsabel Rodríguez, Fagoaga Ramírez, Renán Fernando, Guillén, Luz E., de Jesús Garduño-García, José, Alvirde, Ulices, Ono-Yoshikawa, Yukiko, Choza-Romero, Ricardo, Sauque-Reyna, Leobardo, Garay-Sevilla, Ma. Eugenia, Malacara-Hernandez, Juan M., Tusié-Luna, María Teresa, Gutierrez-Robledo, Luis Miguel, Gómez-Pérez, Francisco J., Rojas, Rosalba, Aguilar-Salinas, Carlos A., Antonio-Villa, Neftali Eduardo, Vargas-Vázquez, Arsenio, Mehta, Roopa, Fermín-Martínez, Carlos A., and Barquera-Guevara, Daphne Abigail

Published
2021
Full Text
View/download PDF

12. May Measurement Month 2017: an analysis of blood pressure screening results worldwide

Author

Napiza-Granada, C, Sevilla, Ma. RC, Atilano, AA, Ona, DID, More, A, Jose, AP, Maheshwari, A, Kondal, D, Yu, W, Li, W, Xu, S, Yu, J, Zhang, H, Widyantoro, B, Turana, Y, Situmorang, TD, Sofiatin, Y, Barack, R, Lin, H-J, Wang, T-D, Chen, W-J, Sirenko, Y, Evstigneeva, O, Negresku, E, Yousif, ME, Medani, SA, Beheiry, HM, Ali, IA, Zilberman, JM, Marin, MJ, Rodriguez, PD, Garcia-Vasquez, F, Kramoh, KE, Ekoua, D, Lopez-Jaramillo, P, Otero, J, Sanchez, G, Narvaez, C, Accini, JL, Hernandez-Hernandez, R, Octavio, JA, Morr, I, Lopez-Rivera, J, Ojji, D, Arije, A, Babatunte, A, Wahab, KW, Fernandes, M, Pereira, SV, Valentim, M, Dzudie, A, Kingue, S, Djomou Ngongang, DA, Ogola, EN, Barasa, FA, Gitura, B, Malik, F-T-N, Choudhury, SR, Al Mamun, MA, Minh, VH, Viet, NL, Cao Truong, S, Ferri, C, Parati, G, Torlasco, C, Borghi, C, Goma, FM, Syatalimi, C, Zelveian, PH, Barbosa, E, Sebba Barroso, W, Penaherrera, E, Jarrin, E, Yusufali, A, Bazargani, N, Tsinamdzgvrishvili, B, Trapaidze, D, Neupane, D, Mishra, SR, Jozwiak, J, Malyszko, J, Konradi, A, Chazova, I, Ishaq, M, Memon, F, Heagerty, AM, Keitley, J, Brady, AJB, Cockcroft, JR, McDonnell, BJ, Lanas, F, Chia, Y-C, Ndhlovu, H, Kiss, I, Ruilope, LM, Ellenga Mbolla, BF, Milhailidou, AS, Woodiwiss, AJ, Perl, S, Dolan, E, Azevedo, V, Garre, L, Boggia, JG, Lee, VWY, Kowlessur, S, Miglinas, M, Sukackiene, D, Wainford, RD, Habonimana, D, Masupe, T, Ortellado, J, Wuerzner, G, Alcocer, L, Burazeri, G, Sanchez Delgado, E, Lovic, D, Mondo, CK, Mostafa, A, Nadar, SK, Valdez Tiburcio, O, Leiba, A, Dorobantu, M, De Backer, T, Chifamba, J, Stergiou, G, Nwokocha, CR, Sokolovic, S, Toure, AI, Connell, KL, Khan, NA, Burger, D, De Carvalho Rodrigues, M, Kramer, BK, Schmieder, RE, Unger, T, Wyss, FS, Yameogo, NV, Beistline, H, Kenerson, JG, Alfonso, B, Olsen, MH, Soares, M, Beaney, Thomas, Schutte, Aletta E, Tomaszewski, Maciej, Ariti, Cono, Burrell, Louise M, Castillo, Rafael R, Charchar, Fadi J, Damasceno, Albertino, Kruger, Ruan, Lackland, Daniel T, Nilsson, Peter M, Prabhakaran, Dorairaj, Ramirez, Agustin J, Schlaich, Markus P, Wang, Jiguang, Weber, Michael A, and Poulter, Neil R

Published
2018
Full Text
View/download PDF

16. Dietary Advanced Glycation End Products and Their Role in Health and Disease

Author

Uribarri, Jaime, del Castillo, María Dolores, de la Maza, María Pía, Filip, Rosana, Gugliucci, Alejandro, Luevano-Contreras, Claudia, Macías-Cervantes, Maciste H, Markowicz Bastos, Deborah H, Medrano, Alejandra, Menini, Teresita, Portero-Otin, Manuel, Rojas, Armando, Sampaio, Geni Rodrigues, Wrobel, Kazimierz, Wrobel, Katarzyna, and Garay-Sevilla, Ma Eugenia

Published
2015
Full Text
View/download PDF

36. List of Contributors

Author

Abd-El-Gawad, Wafaa Mostafa, Achón, María, Anderson, Darrell E., Ashor, Ammar W., Balaskó, Márta, Basso, Andrea, Benlhassan, Khadija, Bernhardt, Jürgen, Boemi, Massimo, Brandt, Kirsten, Bray, Dorothy, Bull, Caroline, Calabrese, Vittorio, Calandra, Carmela, Callejas, Leyda, Calvani, Riccardo, Carding, Simon R., Carvalho, Ana C., Chan, Ruth, Chapman-Novakofski, Karen, Cherbuin, Nicolas, Cherniack, E. Paul, Cheung, Bernice, Choi, Sang-Woon, Chrysohoou, Christina, Chung, Hae Y., Cinzia, Nasuti, Clements, Sarah J., Corcuff, Jean-Benoit, Corsonello, A., Costarelli, Laura, Dang, Weiwei, D’Antona, Giuseppe, Davinelli, Sergio, de Groot, Lisette CPGM, del Balzo, Valeria, Dhillon, Varinderpal, Doets, Esmée L., Dollé, M.E.T., Donatella, Fedeli, Donini, Lorenzo M., Dunn, Barbara K., Dussik, Christopher M., Fenech, Michael, Ford, Dianne, Friso, Simonetta, Furlan, Giorgio, Fusco, S., Garay-Sevilla, Ma. Eugenia, Georgiopoulos, Georgios A., Georgousopoulou, Ekavi N., Giacconi, Robertina, Gilmore, L. Anne, Glibowski, Pawel, Gomes, Andreia C., Gopinath, Bamini, Greenwald, Peter, Griffin, Kristin P., Grúz, Petr, Guichelaar, T., Haussler, Mark R., Heis, Zoe, Incalzi, R. Antonelli, Jahangir, Arshad, Jirillo, Emilio, Jurutka, Peter W., Kahl, Amelie, Kaneko, Ichiro, Khan, Zainab, Kim, Dae Hyun, Koverech, Guido, Kuiper, R.V., Kwan, Macy, Landi, Francesco, Lima, Cristovao F., Lindenau, Ann-Christin, Linnewiel-Hermoni, Karin, Luca, Maria, Luconi, Maria P., Luevano-Contreras, Claudia, Magrone, Thea, Malavolta, Marco, Mallesara, Shwetha, Marcheselli, Fiorella, Marzetti, Emanuele, Mathers, John C., McGregor, Robin A., Merched, Aksam J., Micka, Antje, Miller, Michelle, Mocchegiani, Eugenio, Moreno-Villanueva, María, Orlander, Philip R., Paran, Esther, Pennings, J.L.A., Pereira-Wilson, Cristina, Pétervári, Erika, Piacenza, Francesco, Pierpaoli, Elisa, Poggiogalle, Eleonora, Provinciali, Mauro, Puca, Annibale A., Rasheedy, Doha, Rattan, Suresh I.S., Ravussin, Eric, Recchioni, Rina, Redman, Leanne M., Richmond, Ellen, Rink, Lothar, Rosita, Gabbianelli, Sabir, Marya S., Saini, Rimpi K., Scapagnini, Giovanni, Scichilone, N., Sea, Mandy, Seetharaman, Shyam, Seo, Dae Y., Siepelmeyer, Anne, Siervo, Mario, Sikand, Geeta, Silvestri, Laura, Simm, Andreas, Soós, Szilvia, Spinelli, Chiara Carmela, Suh, Eunkyung, Sultan, Sulaiman, Sun, Yu, Székely, Miklós, Tosato, Matteo, Úbeda, Natalia, Uciechowski, Peter, Valentini, Luzia, van Kerkhof, L.W.M., van Steeg, H., Varela-Moreiras, Gregorio, Villa, Francesco, Wang, Li, Wham, Carol, Whitfield, G. Kerr, Wolak, Talya, Wong, Nathan D., Woo, Jean, and Yu, Byung P.

Published
2016
Full Text
View/download PDF

38. Evolocumab as treatment in lorlatinib-related hyperlipidemia.

Author

Pérez Alonso L, Cervera Calero R, Campos Fernández de Sevilla MÁ, Moreno Palanco MÁ, and Gómez Cerezo JF

Subjects
Humans, Anaplastic Lymphoma Kinase, Lactams, Macrocyclic adverse effects, Protein Kinase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung chemically induced, Lung Neoplasms chemically induced, Hyperlipidemias chemically induced, Hyperlipidemias drug therapy
Abstract

Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer., (Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)

Published
2023
Full Text
View/download PDF

39. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment.

Author

Campos Fernández de Sevilla MÁ, Gallego Úbeda M, Tovar Pozo M, García-Cabrera E, Monje García B, Tutau Gómez F, Delgado Téllez de Cepeda L, and Iglesias-Peinado I

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Sensitivity and Specificity, Surveys and Questionnaires, Treatment Outcome, Viral Load, Antiviral Agents administration & dosage, Hepatitis C drug therapy, Medication Adherence statistics & numerical data, Pharmacy Service, Hospital statistics & numerical data
Abstract

Background Adherence to direct-acting antivirals could be a predictor response to these treatments in hepatitis C. Objective To assess the ability of three methods of measuring adherence to direct-acting antivirals [pill counts, pharmacy dispensing record and Simplified Medication Adherence Questionnaire (SMAQ)] as predictors of their effectiveness. Setting Study conducted by the pharmacy department of the hospital. Methods: A retrospective study was performed. Patients ≥ 18 years with hepatitis C that started and completed treatment with direct-acting antivirals between the 1st-April-2015 and 28st-February-2016 were enrolled. To evaluate the predictive ability to obtain a response to treatment, Chi squared test, Mann-Whitney-U test and ROC-curves were used. Main outcome measure Adherence to antivirals was assessed by three methods and response to treatment, which was defined as obtaining a viral load of hepatitis C virus ≤ 15UI/ml at week 12 after the end of treatment. Results 128 patients were enrolled. The overall average adherence obtained with SMAQ (99.09%) was similar to the pill counts (96.40%, p = 0.043) and pharmacy dispensing record (91.10%, p = 0.02). There was no correlation between the percentage of patients considered as adherent by SMAQ (99.09%) and the achievement of response to treatment (96.40%, p = 0.999). The ROC-curve obtained for the pill count method shows a global area under the curve of 0.53. For pharmacy dispensing record method, patients with an adherence ≤ 66.66% have a high probability of not achieving response (sensitivity and specificity of 79.00% and 100.00%, respectively). Conclusions Pharmacy dispensing record is shown as the best indicator of adherence to predict therapeutic failure in our study.

Published
2019
Full Text
View/download PDF

40. Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.

Author

González-Hernández E, Aparicio R, Garayoa M, Montero MJ, Sevilla MÁ, and Pérez-Melero C

Abstract

The use of multitarget drugs has evolved as an alternative to "magic bullets" for the treatment of complex diseases such as cancer, in order to affect simultaneously several targets relevant to the disease. We have designed and synthesized a series of dual agents as both Eg5 inhibitors and calcium channel blockers, bearing a 4-aryldihydropyrimidine core. Compound 2 (aryl: 3-nitrophenyl) was selected as potential dual agent due to displaying both activities: it is a vasorelaxant agent (>90% relaxation at 10 -5 M in KCl-precontracted aorta rings), it decreases the response to calcium and it is cytotoxic to MCF-7 (breast), HCT-116 (colon) and A-549 (lung) cancer cell lines. The dual mechanism of action was confirmed by blocking (-)-BAY K8644-induced vascular contraction and production of monopolar spindles, typical of Eg5 inhibition. Docking suggests that both ( R ) and ( S )-enantiomers could bind Eg5., (This journal is © The Royal Society of Chemistry 2019.)

Published
2019
Full Text
View/download PDF

41. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.

Author

Campos Fernández de Sevilla MÁ, Gallego Úbeda M, Heredia Benito M, García-Cabrera E, Monje García B, Tovar Pozo M, Delgado Téllez de Cepeda L, and Iglesias-Peinado I

Subjects
Antiviral Agents adverse effects, Female, Hospitals, University organization & administration, Humans, Male, Medication Adherence statistics & numerical data, Middle Aged, Quality Assurance, Health Care, Retrospective Studies, Treatment Outcome, Antiviral Agents therapeutic use, Drug-Related Side Effects and Adverse Reactions prevention & control, Hepatitis C drug therapy, Pharmaceutical Services statistics & numerical data, Program Development statistics & numerical data
Abstract

Background A pharmaceutical care program is necessary to improve the management of direct-acting antivirals in hepatitis C. Objective Describe health outcomes obtained with the implementation of a pharmaceutical care program in Hepatitis C patients treated with direct-acting antivirals. Setting This study was performed in a pharmacy department of a university hospital. Methods Retrospective study between 1st-April 2015 and 28st-February 2016. Hospital pharmacists implemented interventional measures for validation of antivirals prescriptions, detection of drug-interaction, adverse drug events, education and patient´s adherence to antiviral regimen. Main outcome measure Health and quality outcomes of the implementation of the pharmaceutical care program. Results A total 128 patients were enrolled. The overall sustained virologic response at week 12 post-treatment rate was 96.1% (95% CI 92.7-99.5). Adverse drug events occurred in 90.6% of the patients, and the majority were grade 1-2. Pharmacists made 334 pharmaceutical interventions. 35.5% of these interventions were aimed to resolve negative results of drugs. 80.9% of the negative results of drugs improved or were eliminated with the application of the measures proposed by the pharmacists (p ≤ 0.001). Pharmacists carried out 175 preventive interventions to avoid negative results of drugs. 97.3% of these interventions were accepted and managed to prevent the appearance of negative results of drugs (p = 0.453). Conclusion The implementation of a pharmaceutical care program in patients with hepatitis C treated with direct-acting antivirals has improved the safety in the use of these drugs.

Published
2019
Full Text
View/download PDF

42. Sudden Cardiac Death in Professional Soccer Players.

Author

Santos-Lozano A, Martín-Hernández J, Baladrón C, Turrado-Sevilla MÁ, Arrarás-Flores Á, Villacastín JP, Boraita A, Bueno H, and Lucia A

Subjects
Adolescent, Adult, Humans, Male, Soccer physiology, Young Adult, Athletes, Death, Sudden, Cardiac epidemiology, Soccer trends
Published
2017
Full Text
View/download PDF

44. Acute effect of whey peptides upon blood pressure of hypertensive rats, and relationship with their angiotensin-converting enzyme inhibitory activity.

Author

Tavares T, Sevilla MÁ, Montero MJ, Carrón R, and Malcata FX

Subjects
Administration, Oral, Angiotensin I pharmacology, Animals, Bradykinin pharmacology, Lactalbumin chemistry, Lactoglobulins chemistry, Male, Peptide Fragments pharmacology, Rats, Rats, Inbred SHR, Whey Proteins, Antihypertensive Agents pharmacology, Blood Pressure drug effects, Milk Proteins chemistry, Peptides pharmacology, Peptidyl-Dipeptidase A metabolism
Abstract

Scope: The aim of this study was to investigate the antihypertensive effect of a peptide fraction (PepC) obtained from a whey protein concentrate following hydrolysis by Cynara cardunculus, as well as of its fraction with MW below 3 kDa (PepCF). Both these concentrates encompassed peptides that exhibited potent in vitro inhibition of angiotensin-converting enzyme (ACE): two were released from α-lactalbumin--KGYGGVSLPEW and DKVGINYW, and one from β-lactoglobulin--DAQSAPLRVY., Methods and Results: Upon oral administration, by gastric intubation, of 400 mg/kg body weight (bw) of those peptide concentrates, or 5 mg/kg bw of the corresponding synthetic peptides, to 12 wk-old spontaneously hypertensive rats (SHR), the systolic and diastolic blood pressures were monitored by the tail-cuff method--before, and 2, 4, 6, 8 and 24 h afterwards. Water and zofenopril (5 mg/kg bw)--a known ACE-inhibitor, were used as negative and positive controls, respectively. Acute administration of PepC, PepCF, KGYGGVSLPEW, DKVGINYW and DAQSAPLRVY caused antihypertensive effects in SHR; the maximum effect occurred by 4 h and 6 h after administration of the peptide concentrates and the synthetic peptides, respectively. PepC and KGYGGVSLPEW also showed ACE-inhibitory activity in vivo: the pressor effect of angiotensin I was significantly lower, and the response to bradykinin increased when the rats were pre-treated with either product., Conclusion: Our results strongly suggest that PepC will be effective as nutraceutical ingredient for the formulation of functional foods aimed at hypertension control., (© 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)

Published
2012
Full Text
View/download PDF

45. Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits.

Author

Sánchez D, Kassan M, Contreras Mdel M, Carrón R, Recio I, Montero MJ, and Sevilla MÁ

Subjects
Animals, Antihypertensive Agents administration & dosage, Aorta drug effects, Aorta enzymology, Aorta pathology, Blood Pressure drug effects, Caseins administration & dosage, Caseins therapeutic use, Hypertension blood, Hypertension enzymology, Hypertension pathology, Hypertrophy, Left Ventricular drug therapy, Hypertrophy, Left Ventricular pathology, Male, Nitric Oxide Synthase Type III metabolism, Peptidyl-Dipeptidase A blood, Rats, Rats, Inbred SHR, Antihypertensive Agents therapeutic use, Hypertension prevention & control, Milk chemistry
Abstract

Essential hypertension is considered a serious health problem and diet can play an important role in its prevention and treatment. The aim of this study was to evaluate the effect of the long-term intake of a product based on milk casein hydrolysate on the development of hypertension in spontaneously hypertensive rats (SHR). A daily dose of 800 mg/kg body weight of the casein hydrolysate product was administered dissolved in drinking water during 6 weeks. Systolic and diastolic blood pressures were measured weekly by the tail-cuff method. Endothelial function in aorta and mesenteric segments, left ventricular hypertrophy, endothelial nitric oxide synthase (eNOS) expression in aorta and plasmatic angiotensin conversion enzyme (ACE) activity were also evaluated at the end of treatment. The development of hypertension was attenuated in the group treated with the casein hydrolysate product; in this sense the systolic blood pressure increased 33±3 mmHg in control group and only 18±5 mmHg in the treated group during the experimental period. In addition, the treatment improved aorta and mesenteric acetylcholine relaxations and increased the eNOS expression in aorta. Left ventricular hypertrophy decreased in treated SHR accompanied by a significant decrease in interstitial fibrosis. These results warrant evaluation in humans to determine if the product based on a casein hydrolysate could be used as a functional food ingredient to prevent blood pressure increased with additional cardiovascular benefits., (Copyright © 2011 Elsevier Ltd. All rights reserved.)

Published
2011
Full Text
View/download PDF

46. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats.

Author

Monroy-Ruiz J, Sevilla MÁ, Carrón R, and Montero MJ

Subjects
Animals, Aorta metabolism, Aorta physiopathology, Disease Models, Animal, Dose-Response Relationship, Drug, Endothelium, Vascular drug effects, Endothelium, Vascular physiopathology, Hypertension genetics, Hypertension metabolism, Hypertension physiopathology, Hypertrophy, Left Ventricular genetics, Hypertrophy, Left Ventricular metabolism, Hypertrophy, Left Ventricular physiopathology, Male, NADPH Oxidases metabolism, Nitric Oxide metabolism, Oxidative Stress drug effects, Rats, Rats, Inbred SHR, Renal Artery metabolism, Renal Artery physiopathology, Superoxides metabolism, Time Factors, Vascular Resistance drug effects, Vasodilation drug effects, Vasodilator Agents pharmacology, Xanthophylls administration & dosage, Antihypertensive Agents administration & dosage, Aorta drug effects, Blood Pressure drug effects, Diet, Hypertension drug therapy, Hypertrophy, Left Ventricular prevention & control, Renal Artery drug effects
Abstract

The aim of this study was to investigate the effects of astaxanthin-enriched diet on blood pressure, cardiac hypertrophy, both vascular structure and function and superoxide ((*)O(2-)) production in spontaneously hypertensive rats (SHR). Twelve-week-old SHR were treated for 8 weeks with an astaxanthin-enriched diet (75 or 200mg/kg body weight per day). Systolic blood pressure was monitorized periodically during the study by the tail cuff method. At the end of the study animals were sacrificed and heart, kidneys and aorta were removed. Left ventricular weight/body weight ratio was used as left ventricular hypertrophy index (LVH). Vascular function and structure were studied in conductance (aortic rings) and resistance (renal vascular bed) arteries. Also (*)O(2-) production was evaluated by lucigenin-enhanced chemiluminescence. Systolic blood pressure was lower in astaxanthin-treated groups than the control group from the first week of treatment, and LVH was significantly reduced. Astaxanthin improved endothelial function on resistance arteries, but had no effect on aorta. These effects were accompanied by a decrease in oxidative stress and improvements in NO bioavailability. Taken together, these results show that diet supplemented with astaxanthin has beneficial effects on hypertension, by decreasing blood pressure values, improving cardiovascular remodeling and oxidative stress., (Copyright © 2010 Elsevier Ltd. All rights reserved.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results